EMD Millipore Expands its Emprove Raw Materials Portfolio - - BioPharm International

ADVERTISEMENT

EMD Millipore Expands its Emprove Raw Materials Portfolio



EMD Millipore, the life-science division of Merck KGaA, reported the expansion of its Emprove raw materials portfolio to 400 APIs, excipients, and biopharmaceutical materials. The products offer detailed application-specific documentation in addition to increased quality, allowing pharmaceutical manufacturers to reduce qualification costs and accelerate time-to-market processes, according to the company.

The portfolio includes Emprove api for APIs, Emprove exp for excipients, and Emprove bio for biopharmaceutical materials, which provide the documentation to improve transparency and efficiency. The revised documentation, prepared in an internationally accepted format, prevents errors from gathering information manually and minimizes risk to patients, according to the company.

Depending on the application, the Emprove documentation can contain information regarding manufacturer and manufacturing process details, testing procedures, purity, and stability data. The APIs are manufactured according to cGMP guideline ICH Q7, the excipients are EXCiPACT certified, and the biopharmaceutical materials can be used in both upstream and downstreamprocess steps.

Source: EMD Millipore
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here